Longboard Pharmaceuticals
About:
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases.
Website: https://www.longboardpharma.com/
Twitter/X: longboardp
Top Investors: Farallon Capital Management, Cormorant Asset Management, Highline Capital Management, HBM Healthcare Investments, T. Rowe Price
Description:
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
$79M
$1M to $10M
San Diego, California, United States
2020-01-01
info(AT)longboardpharma.com
Kevin R. Lind
11-50
2024-01-02
Public
© 2025 bioDAO.ai